Alexander O. Schuth M.D.
Net Worth

Last updated:

What is Alexander O. Schuth M.D. net worth?

The estimated net worth of Dr. Alexander O. Schuth M.D. is at least $27,687,533 as of 22 Nov 2024. He owns shares worth $2,635,377 as insider, has earned $19,309,916 from insider trading and has received compensation worth at least $5,742,240 in Denali Therapeutics Inc..

What is the salary of Alexander O. Schuth M.D.?

Dr. Alexander O. Schuth M.D. salary is $820,320 per year as Co-Founder, Chief Operating Officer & Sec. in Denali Therapeutics Inc..

How old is Alexander O. Schuth M.D.?

Dr. Alexander O. Schuth M.D. is 52 years old, born in 1973.

What stocks does Alexander O. Schuth M.D. currently own?

As insider, Dr. Alexander O. Schuth M.D. owns shares in one company:

Company Title Shares Price per share Total value
Denali Therapeutics Inc. (DNLI) Co-Founder, Chief Operating Officer & Sec. 178,066 $14.8 $2,635,377

What does Denali Therapeutics Inc. do?

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI logo
DNLI
Denali Therapeutics Inc.
$14.8

Alexander O. Schuth M.D. insider trading

Denali Therapeutics Inc.

Dr. Alexander O. Schuth M.D. has made 82 insider trades between 2018-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 70,000 units of DNLI stock on 4 Jan 2021. As of 22 Nov 2024 he still owns at least 178,066 units of DNLI stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (right to buy) 20,516 $0.68 $13,951
Option
Common Stock 20,516 $0.68 $13,951
Option
Stock Option (right to buy) 15,558 $5.28 $82,146
Sale
Common Stock 12,333 $29.68 $366,043
Sale
Common Stock 2,925 $30.72 $89,856
Sale
Common Stock 300 $31.29 $9,387
Option
Common Stock 15,558 $5.28 $82,146
Sale
Common Stock 2,547 $24.78 $63,115
Sale
Common Stock 3,353 $23.54 $78,930
Sale
Common Stock 2,453 $23.79 $58,357
Sale
Common Stock 2,272 $22.89 $52,006
Sale
Common Stock 20,128 $17.66 $355,460
Sale
Common Stock 2,716 $17.29 $46,960
Option
Stock Option (right to buy) 50,000 $0.68 $34,000
Option
Common Stock 50,000 $0.68 $34,000
Sale
Common Stock 9,972 $19.43 $193,756
Sale
Common Stock 2,522 $23.17 $58,435
Sale
Common Stock 2,478 $22.59 $55,978
Sale
Common Stock 2,772 $23.67 $65,613
Sale
Common Stock 2,853 $24.18 $68,986
Sale
Common Stock 9,702 $30.01 $291,157
Option
Common Stock 10,000 $5.28 $52,800
Option
Stock Option (right to buy) 10,000 $5.28 $52,800
Sale
Common Stock 10,000 $29.6 $296,000
Option
Stock Option (right to buy) 10,000 $5.28 $52,800
Option
Common Stock 10,000 $5.28 $52,800
Sale
Common Stock 800 $29.23 $23,384
Sale
Common Stock 9,200 $28.55 $262,660
Option
Common Stock 4,898 $5.28 $25,861
Sale
Common Stock 4,898 $25.04 $122,646
Option
Stock Option (right to buy) 4,898 $5.28 $25,861
Option
Common Stock 5,102 $5.28 $26,939
Option
Stock Option (right to buy) 5,102 $5.28 $26,939
Option
Stock Option (right to buy) 25,000 $0.68 $17,000
Option
Common Stock 25,000 $0.68 $17,000
Sale
Common Stock 3,497 $30.09 $105,225
Sale
Common Stock 1,521 $30.89 $46,984
Sale
Common Stock 114 $29.87 $3,405
Sale
Common Stock 9,886 $29.53 $291,934
Option
Common Stock 10,000 $5.28 $52,800
Option
Stock Option (right to buy) 10,000 $5.28 $52,800
Sale
Common Stock 2,636 $28.44 $74,968
Sale
Common Stock 2,912 $28.7 $83,574
Sale
Common Stock 2,912 $28.7 $83,574
Option
Stock Option (right to buy) 20,000 $0.68 $13,600
Option
Common Stock 20,000 $0.68 $13,600
Sale
Common Stock 2,576 $33.22 $85,575
Sale
Common Stock 2,803 $34.68 $97,208
Sale
Common Stock 1,423 $37.11 $52,800
Sale
Common Stock 2,846 $44.77 $127,415
Sale
Common Stock 7,200 $42.45 $305,640
Sale
Common Stock 2,800 $41.82 $117,096
Sale
Common Stock 10,000 $52.94 $529,400
Sale
Common Stock 10,000 $50.64 $506,400
Option
Common Stock 9,045 $0.68 $6,151
Option
Stock Option (right to buy) 9,045 $0.68 $6,151
Sale
Common Stock 10,000 $55.47 $554,730
Sale
Common Stock 2,544 $49.83 $126,768
Sale
Common Stock 10,000 $52.28 $522,820
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 $64.58 $645,810
Sale
Common Stock 10,000 $56.13 $561,320
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 $56.5 $565,020
Sale
Common Stock 10,000 $56.5 $565,020
Sale
Common Stock 10,000 $56.5 $565,020
Sale
Common Stock 10,000 $61.23 $612,340
Sale
Common Stock 10,000 $61.23 $612,340
Sale
Common Stock 3,047 $70.79 $215,694
Sale
Common Stock 3,047 N/A N/A
Sale
Common Stock 1,468 $75.17 $110,351
Option
Common Stock 4,250 N/A N/A
Option
Restricted Stock Units 4,250 N/A N/A
Sale
Common Stock 10,000 $67.72 $677,180
Sale
Common Stock 10,000 $67.72 $677,180
Sale
Common Stock 70,000 $74.87 $5,240,760
Sale
Common Stock 56,575 N/A N/A
Option
Common Stock 5,643 N/A N/A
Option
Restricted Stock Units 5,643 N/A N/A
Sale
Common Stock 1,427 $19.49 $27,812
Option
Restricted Stock Units 4,250 N/A N/A
Option
Common Stock 4,250 N/A N/A
Sale
Common Stock 5,777 $18 $103,986
Option
Stock Option (right to buy) 3,121 $18 $56,178
Option
Common Stock 3,121 $18 $56,178
Option
Stock Option (right to buy) 711 $5.28 $3,754
Option
Common Stock 711 $5.28 $3,754
Sale
Common Stock 1,723 $11.65 $20,064
Sale
Common Stock 229 $18.02 $4,127
Sale
Common Stock 14,125 $18.02 $254,533
Sale
Common Stock 646 $18 $11,628
Option
Stock Option (right to buy) 5,129 $5.28 $27,081
Option
Common Stock 5,129 $5.28 $27,081
Sale
Common Stock 7,500 $18.16 $136,200
Option
Common Stock 5,643 N/A N/A
Option
Restricted Stock Units 5,643 N/A N/A
Sale
Common Stock 7,500 $18.81 $141,075
Sale
Common Stock 7,500 $20.58 $154,313
Sale
Common Stock 7,500 $18.77 $140,775
Sale
Common Stock 2,500 $21.09 $52,725
Sale
Common Stock 2,500 $21.09 $52,725
Sale
Common Stock 2,500 $21.09 $52,725
Sale
Common Stock 2,512 $27.73 $69,658
Sale
Common Stock 2,513 $28.26 $71,017
Sale
Common Stock 2,475 $28.17 $69,721
Sale
Common Stock 2,512 $23.97 $60,200
Sale
Common Stock 2,513 $22.4 $56,291
Sale
Common Stock 2,475 $21.5 $53,213
Sale
Common Stock 2,500 $19.99 $49,963
Sale
Common Stock 2,500 $19.05 $47,613
Sale
Common Stock 2,500 $18.11 $45,275
Sale
Common Stock 2,500 $20.8 $52,000
Sale
Common Stock 2,500 $20.8 $52,000
Sale
Common Stock 2,500 $20.8 $52,000
Sale
Common Stock 2,500 $20.8 $52,000
Sale
Common Stock 2,500 $20.8 $52,000
Sale
Common Stock 2,500 $20.8 $52,000
Option
Common Stock 5,859 $9.6 $56,246
Option
Stock Option (right to buy) 7,043 $7.44 $52,400
Option
Stock Option (right to buy) 1,184 $5.28 $6,252
Option
Common Stock 7,043 $7.44 $52,400
Option
Common Stock 5,918 $5.28 $31,247
Option
Stock Option (right to buy) 5,918 $5.28 $31,247

Denali Therapeutics key executives

Denali Therapeutics Inc. executives and other stock owners filed with the SEC: